352 material Form 8-K filings that 310 companies we cover made with the SEC in August 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Regency Centers reported second-quarter 2024 results on August 1, 2024, with net income attributable to common shareholders of $0.54 per diluted share, up from $0.51 a year earlier. The REIT raised its full-year 2024 Nareit FFO guidance to $4.21 to $4.25 per diluted share from $4.15 to $4.21, which signals higher expected operating results for shareholders.
Q2 2024 Nareit FFO was $1.06 per diluted share, up from $1.03 in Q2 2023; Core Operating Earnings was $1.02, up from $0.96.
2024 Nareit FFO guidance raised to $4.21 to $4.25 per diluted share; Core Operating Earnings guidance raised to $4.06 to $4.10.
Same Property NOI rose 3.3% excluding lease termination fees and collection of 2020-2021 reserves; Same Property percent leased was 95.8%.
On July 31, 2024, the board authorized a new share repurchase program of up to $250 million and declared a $0.67 quarterly common dividend.
LeMaitre Vascular reported preliminary second-quarter 2024 results, with sales of $55.8 million, up 11% from a year earlier, and net income of $11.8 million, up 46%. The company raised its full-year 2024 guidance, now projecting sales of $216.8 million to $220.8 million and EPS of $1.82 to $1.91, which shareholders will weigh alongside the company's higher quarterly profitability.
Q2 2024 sales $55.8 million, up 11% (12% organic); diluted EPS $0.52, up 44%
Gross margin 68.9%, up from 64.0% in Q2 2023; operating income $14.4 million, up 52%
Full-year 2024 guidance: sales $216.8 million to $220.8 million; EPS $1.82 to $1.91
Quarterly dividend of $0.16 per share payable August 29, 2024, to holders of record August 15, 2024
Bio-Rad reported second-quarter 2024 net sales of $638.5 million, down 6.3% from a year earlier, and a GAAP net loss of $2,165.5 million, driven by a change in the fair market value of its Sartorius AG investment. The company lowered its full-year 2024 outlook, now expecting non-GAAP revenue to decline 2.5% to 4.0% on a currency-neutral basis, and its board raised the buyback authorization by $500 million.
Q2 2024 net sales were $638.5 million, down 6.3% from $681.1 million; Life Science fell 16.5% and Clinical Diagnostics rose 2.1%.
GAAP net loss was $2,165.5 million, or $76.26 per diluted share, versus a loss of $39.59 per share a year earlier; non-GAAP EPS was $3.11 versus $3.00.
Full-year 2024 non-GAAP revenue outlook moved to a 2.5% to 4.0% decline from prior 1.0% to 2.5% growth; non-GAAP operating margin outlook cut to 12.0% to 13.0% from 13.5% to 14.0%.
On July 29, 2024, the board authorized up to an additional $500 million in repurchases; about $578 million was available as of July 31, 2024.
Universal Display reported second quarter 2024 revenue of $158.5 million, up from $146.6 million a year earlier, and net income of $52.3 million, or $1.10 per diluted share, versus $1.04 a year earlier. The company raised the lower end of its 2024 revenue guidance to a range of $645 million to $675 million, while operating income and gross margin both declined year over year.
Q2 2024 total revenue was $158.5 million, compared with $146.6 million in Q2 2023.
Q2 2024 net income was $52.3 million, or $1.10 per diluted share, compared with $49.7 million, or $1.04 per diluted share.
Operating income fell to $56.4 million from $58.6 million, and total gross margin was 76% versus 78%.
2024 revenue guidance is now $645 million to $675 million; the company also declared a third quarter dividend of $0.40 per share, payable September 30, 2024.
Dorman Products reported second-quarter 2024 net sales of $503.0 million, up 4.7%, and diluted EPS of $1.53, up 47% from a year earlier. The company raised its full-year 2024 diluted EPS guidance to $5.32 to $5.52, from $4.71 to $5.01, which gives shareholders a higher profit outlook. Heavy Duty and Specialty Vehicle sales declined in the quarter.
Net sales were $503.0 million, up 4.7% from $480.6 million; Light Duty rose 9%, while Heavy Duty fell 11% and Specialty Vehicle fell 2%.
Diluted EPS was $1.53 versus $1.04; adjusted diluted EPS was $1.67 versus $1.01.
2024 diluted EPS guidance was raised to $5.32 to $5.52 from $4.71 to $5.01; adjusted diluted EPS guidance is $6.00 to $6.20.
The company repurchased $25 million of its shares and will hold a conference call on August 2, 2024 at 8:00 a.m. Eastern.
Tanger reported second-quarter 2024 results and raised its full-year 2024 Core FFO guidance to $2.05 to $2.12 per share from $2.03 to $2.11. Core FFO and FFO per share both rose to $0.53 from $0.47, while diluted net income per share slipped to $0.22 from $0.23. The higher guidance and rising funds from operations point to improved operating results for shareholders.
Q2 2024 total revenues were $129.0 million, compared with $110.6 million in Q2 2023.
Q2 2024 diluted net income per share was $0.22, versus $0.23 a year earlier; FFO and Core FFO were $0.53 per share, versus $0.47.
Full-year 2024 Core FFO guidance rose to $2.05 to $2.12 per share from $2.03 to $2.11.
Board authorized a quarterly cash dividend of $0.275 per share, payable August 15, 2024.
Alignment Healthcare reported second-quarter 2024 revenue of $681.3 million, up 47.3% from a year earlier, and a net loss of $24.0 million, narrowed from $28.5 million. The company raised its year-end membership and revenue guidance and kept its full-year adjusted gross profit and adjusted EBITDA guidance unchanged, which shows the larger revenue base is also producing a smaller loss.
Total revenue was $681.3 million, up 47.3% year over year, and health plan membership was about 175,100, up 56.1%.
Adjusted EBITDA was $6.0 million, compared with a loss of $2.1 million a year earlier; net loss was $24.0 million versus $28.5 million.
Full-year 2024 revenue guidance was raised to $2.61 billion to $2.64 billion, and year-end membership guidance was raised to 178,000 to 180,000.
Full-year adjusted gross profit ($280 million to $310 million) and adjusted EBITDA (–$12 million to $12 million) guidance was maintained.
Schneider National reported second quarter 2024 operating revenues of $1,316.7 million, down 2% from $1,346.5 million a year earlier, while income from operations fell 51% to $51.0 million and diluted EPS dropped to $0.20 from $0.43. The company also lowered its full-year 2024 adjusted diluted EPS guidance to $0.80-$0.90 from $0.85-$1.00, citing slower-than-expected pricing gains, which signals weaker profit expectations for shareholders.
Q2 2024 income from operations was $51.0 million versus $103.8 million in Q2 2023; diluted EPS was $0.20 versus $0.43.
Full-year 2024 adjusted diluted EPS guidance was cut to $0.80-$0.90 from $0.85-$1.00.
Net capital expenditures guidance was lowered to $300.0-$350.0 million from $350.0-$400.0 million.
Q2 2024 free cash flow was $112.9 million, compared with negative $57.1 million in Q2 2023.
IDACORP reported second quarter 2024 net income attributable to IDACORP of $89.5 million, or $1.71 per diluted share, up from $68.6 million, or $1.35 per diluted share, a year earlier. The company raised the low end of its full-year 2024 earnings guidance to $5.30 to $5.45 per diluted share from $5.25 to $5.45, citing higher customer usage, customer growth and rate changes, partly offset by higher depreciation.
Q2 2024 net income $89.5 million ($1.71 per diluted share) vs. $68.6 million ($1.35) in Q2 2023
Six-month 2024 earnings $2.67 per diluted share vs. $2.46 in the first half of 2023
2024 earnings guidance now $5.30 to $5.45 per diluted share vs. previous $5.25 to $5.45, as of August 1, 2024
Idaho Power expects to use $35 million to $50 million of additional tax credits in 2024, with the range previously $35 million to $60 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.